Insulet CEO Buys $162K in Company Stock

According to the latest SEC filing disclosure, a significant insider purchase transaction occurred on August 24 involving Insulet President and CEO Ashley McEvoy.

What happened: McEvoy purchased 1,100 shares of Insulet stock via a Form 4 filed with the U.S. Securities and Exchange Commission. The total transaction value was $162,217.

During Monday morning trading, Insulet shares were down 0.04%, currently quoted at $148.09.

A Deeper Look at Insulet's Background

Founded in 2000, Insulet's goal was to make continuous subcutaneous insulin infusion therapy easier to use for diabetes patients. The result is the Omnipod system, which consists of a small, disposable insulin infusion device that can be operated via smartphone to control dosing. Since Omnipod received FDA approval in 2005, more than 600,000 insulin-dependent diabetes patients worldwide have used the product.

Insulet: In-Depth Financial Analysis

Revenue Growth: Insulet demonstrated notable revenue growth over a 3-month period. As of June 30, 2026, the company achieved a revenue growth rate of approximately 23.51%. This indicates a significant increase in top-line revenue. Compared to competitors, the company's growth rate exceeded the average of peers in the healthcare industry.

Profitability Metrics: Unlocking Value

Gross Margin: The company performed strongly with a notable gross margin of 70.18%, demonstrating superior cost efficiency and profitability relative to industry peers.

Earnings Per Share: Insulet's EPS performance stands out, reflecting a positive bottom-line trend and exceeding the industry average, with current EPS at 1.37.

Debt Management: Insulet's debt-to-equity ratio is significantly higher than the industry average. At 0.67, this indicates greater reliance on borrowed funds, suggesting a higher level of financial risk.

In-Depth Valuation Check:

P/E Ratio: The current P/E ratio of 27.8 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity.

P/S Ratio: The current P/S ratio of 3.47 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for investors considering sales performance.

EV/EBITDA Analysis: Insulet's EV/EBITDA ratio of 16.37 is below the industry average and can be considered undervalued.

Market Cap Analysis: Reflecting a smaller scale, the company's market cap is below the industry average. This may be attributed to factors such as growth expectations or operational capabilities.

Why Insider Transactions Matter

Insider transactions should not be used primarily for making investment decisions, but they can be a significant factor in investment decisions.

Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than 10% of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executive-level personnel and major hedge funds. These insiders must disclose their transactions via Form 4, which should be filed within two business days after the transaction.

A new purchase initiated by a company insider is a strong signal that they expect the stock to rise.

However, insider selling may not always indicate a bearish view and can be influenced by various factors.

Transaction Codes to Watch

When closely examining transactions, investors typically prioritize open-market transactions, which are cataloged in Part I of the Form 4 filing. A P in Box 3 indicates a purchase, while an S indicates a sale. Transaction code C indicates an option conversion, and transaction code A indicates a conversion, award, or other acquisition of securities from the company.

View the full list of Insulet insider transactions.

This article was generated by an automated content engine and reviewed by an editor.